Evidence map›Paper›PMID 42095215›Full record

ArticleOpen forum infectious diseases2026

Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review.

Filip Pavlovic, Richard Kwizera, David W Denning

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Filip PavlovicSchool of Medicine, The University of Manchester, Manchester, UK.
Richard KwizeraInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.ORCID https://orcid.org/0000-0002-5270-3539
David W DenningManchester Fungal Infection Group, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.ORCID https://orcid.org/0000-0001-5626-2251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic pulmonary aspergillosis (CPA) affects those with underlying lung conditions or mild immunocompromise. Chronic pulmonary aspergillosis carries a poor prognosis in adults. Its pathogenesis remains obscure. We summarize all cases of CPA in children globally. Methods: From 6503 screened reports, we reviewed the full text of 604, of which 44 fit the inclusion criteria and an additional 11 other cases with little detail which were included under Supplementary Data. Chronic granulomatous disease and cystic fibrosis cases were excluded. Results: We found 47 well-documented individual cases of CPA in children published from 1963 to 2022. Twenty-two cases were simple aspergillomas, and 11 were chronic cavitary pulmonary aspergillosis. Ages ranged from under 1 year to 17 years old, and 28 (59.8%) were male. Eighteen (38.3%) cases had no reported underlying disease. Underlying diseases included pulmonary tuberculosis (14.9%), Job's Syndrome (10.6%), congenital pulmonary airway malformation (8.5%), allergic bronchopulmonary aspergillosis or asthma (6.4%), pulmonary hydatid cyst (4.3%), bacterial pneumonia with cavitation (4.3%), diabetes mellitus (4.3%), and single cases of pulmonary sequestration or bronchogenic cyst. All cases had either microbiological or immunological evidence of Conclusions: Chronic pulmonary aspergillosis is apparently rare in children but does occur, often with no antecedent condition. Prognosis is good with early diagnosis.

Indexed as

aspergillomaAspergillus fumigatushyper-IgE syndromelobectomymortality

Identifiers

PMID42095215
PMCPMC13138880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.